Nitric Oxide in Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO)

Overview

This pilot study is designed to investigate the effect of inhaled nitric oxide on cardiac, pulmonary artery, and systemic hemodynamics at various time points during venoarterial extracorporeal membrane oxygenation (VA-ECMO) support. Patients who have been initiated on VA-ECMO will be invited to participate. Inhaled nitric oxide (iNO) will be used early after VA-ECMO cannulation (once consent is obtained). After baseline hemodynamic, biochemical, and echocardiographic parameters are assessed, iNO will be initiated and all parameters will be reassessed after 30 minutes and 6 hours. Inhaled nitric oxide will then be discontinued and all parameters repeated. At the time of VA-ECMO weaning (timing determined by clinical team), iNO will be reinitiated with repeat assessment of hemodynamic, biochemical, and echocardiographic parameters both prior to the wean and after the wean (whether successful or not).

Full Title of Study: “Nitric Oxide in Right Ventricular Dysfunction: Improvements in Clinical and Hemodynamic Parameters on Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO; NOVICE)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 28, 2022

Detailed Description

This is a proof of concept, pilot, phase II study using iNO in patients on VA-ECMO. Stage 1 will assess the participant's response to iNO early after cannulation. Stage 2 will assess the participant's response to iNO during the ECMO weaning process. Stage 1 Patients in whom VA-ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration and repeated 30 minutes after iNO initiation. iNO will be continued for six hours to allow hemodynamic and oxygenation parameters to stabilize as per previous protocols in the literature. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be discontinued. All parameters will be re-evaluated 30 minutes after iNO discontinuation. Stage 2 A weaning trial will be performed at 1) the earliest signs of myocardial recovery or b) day 5. Myocardial recovery will be defined as: mean arterial pressure > 60 millimeters of mercury (mmHg) on no or minimal inotropic/vasopressor support, arterial pulse pressure > 10 mmHg, and minimal respiratory support (oxygen saturation > 88% on < 2 liters by nasal cannulae, or minimal ventilator setting if intubated). Inhaled nitric oxide will be re-initiated 30 minutes prior to the ECMO weaning trial. Adequacy of perfusion will be defined as a mixed venous oxygen saturation of > 70%. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. ECMO will be weaned as per the standard protocol at the University Health Network with re-assessment of all parameters after weaning is complete. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA-ECMO and 30 minutes thereafter. VA-ECMO weaning will be re-attempted at 24-48 hours at the discretion of the medical team.

Interventions

  • Drug: Inhaled nitric oxide
    • Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation. Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation.

Arms, Groups and Cohorts

  • Inhaled nitric oxide

Clinical Trial Outcome Measures

Primary Measures

  • Participant recruitment
    • Time Frame: February 2020
    • Recruitment of ten participants
  • Right Heart – Qualitative function, change from baseline
    • Time Frame: After 6 hours of inhaled nitric oxide
    • Mild/moderate/severe dysfunction as determined by reading echocardiographer
  • Right Heart – Tricuspid annular plane systolic excursion (TAPSE), change from baseline
    • Time Frame: After 6 hours of inhaled nitric oxide
    • Measured in milimeters
  • Right Heart – RV fractional area change, change from baseline
    • Time Frame: After 6 hours of inhaled nitric oxide
    • Measured in percent
  • Right Heart – longitudinal myocardial velocity (S’), change from baseline
    • Time Frame: After 6 hours of inhaled nitric oxide
    • Measured in meters per second

Secondary Measures

  • Left Heart Function
    • Time Frame: After 6 hours of inhaled nitric oxide
    • Left ventricular ejection fraction
  • Weaning success
    • Time Frame: Within 5 days of cannulation but may be repeated at 7 days if initially unsuccessful.
    • Explore the effect of iNO on the rate of successful VA ECMO weaning.
  • Long-term RV function
    • Time Frame: Within three months of initial ECMO cannulation.
    • Assess RV function after LVAD implantation or cardiac transplantation if these occur during the same hospitalization.

Participating in This Clinical Trial

Inclusion Criteria

  • Age>18years – History or evidence of left ventricular failure Exclusion Criteria:

  • ECMO cannulation site other than the femoral vein and artery – Insufficient echocardiographic images to assess ventricular function – Right ventricular assist device – Uncorrected congenital heart disease – Primary graft failure – No cardiac output on bedside ECHO (LVEF<5%) – Pregnant or breastfeeding

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Filio Billia
  • Collaborator
    • Peter Munk Cardiac Center
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Filio Billia, Director of Research, Peter Munk Cardiac Center – University of Toronto
  • Overall Official(s)
    • Filio Billia, MD PhD, Principal Investigator, University of Toronto, Peter Munk Cardiac Centre
  • Overall Contact(s)
    • Andrea L Daly, MD, 16475457454, andrealdaly@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.